(P057) A Population-Based Study of Men With Low-Volume, Low-Risk Prostate Cancer: Does African-American Race Predict for More Aggressive Disease?

OncologyOncology Vol 29 No 4_Suppl_1
Volume 29
Issue 4_Suppl_1

In this large population-based cohort of 1,794 men with low-risk, low-volume prostate cancer, AA race was not associated with more aggressive pathology compared with Caucasians.

Arpit Chhabra, MD, Justin Rineer, MD, Jeremy Weedon, PhD, David Schreiber, MD; State University of New York Downstate Medical Center; University of Florida Orlando Health; Department of Veterans Affairs, New York Harbor Healthcare System

INTRODUCTION: Recent studies have suggested that African-American (AA) patients with clinical low-risk prostate cancer may not be ideal candidates for active surveillance due to a higher likelihood of harboring aggressive disease. In this study, we utilized the Surveillance, Epidemiology, and End Results (SEER) database to analyze whether race plays a role in pathological upstaging after radical prostatectomy (RP).

MATERIALS AND METHODS: This study consisted of patients in the SEER database for whom race was identified either as white or AA. Eligible men were diagnosed between 2010 and 2011 with prostate-specific antigen (PSA) < 10 ng/mL as well as cT1cN0M0, Gleason score 6 disease with adenocarcinoma in 2 or fewer cores of a ≥ 12-core biopsy, treated by RP. Detailed pathologic information regarding pathologic T stage, margin status, and primary and secondary pathologic Gleason scores were collected. Adverse pathology was characterized individually, as well as in a composite metric, which was defined as pT2 and Gleason ≥ 4 + 3; pT3a and Gleason 3 + 3 with positive margins; pT3a and Gleason ≥ 3 + 4; or pT3b–pT4 with any Gleason score. We also analyzed the Cancer of the Prostate Risk Assessment score (CAPRA-S) for each patient. Chi-square was used to characterize differences in pathological extent of disease by race. Univariate and multivariate logistic regression was used to look for potential predictors for adverse pathology. Statistical significance was defined as a P value of < .05.

RESULTS: There were a total of 1,794 patients who met the selection criteria, of whom 1,565 (87.2%) were identified as white and 229 (12.8%) were identified as AA. No statistical difference was observed between white and AA men with regard to pathological Gleason score (P = .99), pathological extent of disease (P = .34), margin status (P = .43), CAPRA-S score (P = .56), or adverse features (P = .45). On multivariate analysis, only increasing PSA and increasing age were significant predictors of adverse pathology. AA race was not predictive for adverse pathology on univariate (odds ratio [OR] = 1.19; 95% confidence interval [CI], 0.75–1.88; P = .45) or multivariate (OR = 1.43; 95% CI, 0.87–2.33; P = .16) analysis.

CONCLUSION: In this large population-based cohort of 1,794 men with low-risk, low-volume prostate cancer, AA race was not associated with more aggressive pathology compared with Caucasians.

Proceedings of the 97th Annual Meeting of the American Radium Society- americanradiumsociety.org

Articles in this issue

(P005) Ultrasensitive PSA Identifies Patients With Organ-Confined Prostate Cancer Requiring Postop Radiotherapy
(P001) Disparities in the Local Management of Breast Cancer in the United States According to Health Insurance Status
(P002) Predictors of CNS Disease in Metastatic Melanoma: Desmoplastic Subtype Associated With Higher Risk
(P003) Identification of Somatic Mutations Using Fine Needle Aspiration: Correlation With Clinical Outcomes in Patients With Locally Advanced Pancreatic Cancer
(P004) A Retrospective Study to Assess Disparities in the Utilization of Intensity-Modulated Radiotherapy (IMRT) and Proton Therapy (PT) in the Treatment of Prostate Cancer (PCa)
(S001) Tumor Control and Toxicity Outcomes for Head and Neck Cancer Patients Re-Treated With Intensity-Modulated Radiation Therapy (IMRT)-A Fifteen-Year Experience
(S003) Weekly IGRT Volumetric Response Analysis as a Predictive Tool for Locoregional Control in Head and Neck Cancer Radiotherapy 
(S004) Combination of Radiotherapy and Cetuximab for Aggressive, High-Risk Cutaneous Squamous Cell Cancer of the Head and Neck: A Propensity Score Analysis
(S005) Radiotherapy for Carcinoma of the Hypopharynx Over Five Decades: Experience at a Single Institution
(S002) Prognostic Value of Intraradiation Treatment FDG-PET Parameters in Locally Advanced Oropharyngeal Cancer
(P006) The Role of Sequential Imaging in Cervical Cancer Management
(P008) Pretreatment FDG Uptake of Nontarget Lung Tissue Correlates With Symptomatic Pneumonitis Following Stereotactic Ablative Radiotherapy (SABR)
(P009) Monte Carlo Dosimetry Evaluation of Lung Stereotactic Body Radiosurgery
(P010) Stereotactic Body Radiotherapy for Treatment of Adrenal Gland Metastasis: Toxicity, Outcomes, and Patterns of Failure
(P011) Stereotactic Radiosurgery and BRAF Inhibitor Therapy for Melanoma Brain Metastases Is Associated With Increased Risk for Radiation Necrosis
Related Videos
Collaboration among nurses, social workers, and others may help in safely administering outpatient bispecific T-cell engager therapy to patients.
Nurses should be educated on cranial nerve impairment that may affect those with multiple myeloma who receive cilta-cel, says Leslie Bennett, MSN, RN.
Treatment with cilta-cel may give patients with multiple myeloma “more time,” according to Ishmael Applewhite, BSN, RN-BC, OCN.
Nurses may need to help patients with multiple myeloma adjust to walking differently in the event of peripheral neuropathy following cilta-cel.
Tailoring neoadjuvant therapy regimens for patients with mismatch repair deficient gastroesophageal cancer represents a future step in terms of research.
Not much is currently known about the factors that may predict pathologic responses to neoadjuvant immunotherapy in this population, says Adrienne Bruce Shannon, MD.
Data highlight that patients who are in Black and poor majority areas are less likely to receive liver ablation or colorectal liver metastasis in surgical cancer care.
Findings highlight how systemic issues may impact disparities in outcomes following surgery for patients with cancer, according to Muhammad Talha Waheed, MD.
Pegulicianine-guided breast cancer surgery may allow practices to de-escalate subsequent radiotherapy, says Barbara Smith, MD, PhD.
Adrienne Bruce Shannon, MD, discussed ways to improve treatment and surgical outcomes for patients with dMMR gastroesophageal cancer.
Related Content